Shulin Li, PhD

Peer-Reviewed Articles

1. Zhang S, Rao G, Heimberger A, Li S. Fibrinogen-Like Protein 2: Biological Function across Cell Types and Immune Therapeutic Potential for Gliomas. Cytokine Growth Factor Rev 69:73-79, 2023. PMID: 36085259.
2. Bai W, Kuang T, Chitrakar C, Yang R, Li S, Zhu D, Chang L. Patchable micro/nanodevices interacting with skin. Biosens Bioelectron 122:189-204, 2018. e-Pub 2018. PMID: 30265969.
3. Noh H, Zhao Q, Yan J, Kong LY, Gabrusiewicz K, Hong S, Xia X, Heimberger AB, Li S. Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells. Cancer Lett 433:176-185, 2018. e-Pub 2018. PMID: 29991446.
4. Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A, Li X, Lorenzi PL, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Ravikumar V, Manyam G, Rao A, Shelley S, Liu Y, Ju Z, Hansel D, de Velasco G, Pennathur A, Andersen JB, O'Rourke CJ, Ohshiro K, Jogunoori W, Nguyen BN, Li S, Osmanbeyoglu HU, Ajani JA, Mani SA, Houseman A, Wiznerowicz M, Chen J, Gu S, Ma W, Zhang J, Tong P, Cherniack AD, Deng C, Resar L, Cancer Genome Atlas Research Network, Weinstein JN, Mishra L, Akbani R. A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily. Cell Syst 7(4):1-16, 2018. e-Pub 2018. PMID: 30268436.
5. Luk BT, Jiang Y, Copp JA, Hu CJ, Krishnan N, Gao W, Li S, Fang RH, Zhang L. Biomimetic Targeting of Nanoparticles to Immune Cell Subsets via Cognate Antigen Interactions. Mol Pharm 15(9):3723-3728, 2018. e-Pub 2018. PMID: 29533668.
6. Hu J, Sun C, Bernatchez C, Xia X, Hwu P, Dotti G, Li S. T cell homing therapy for reducing regulatory T cells and preserving effector T cell function in large solid tumors. Clin Cancer Res 24(12):2920-2934, 2018. e-Pub 2018. PMID: 29391351.
7. Li H, Meng QH, Noh H, Somaiah N, Torres KE, Xia X, Batth IS, Joseph CP, Liu M, Wang R, Li S. Cell-surface vimentin-positive macrophage-like circulating tumor cells as a novel biomarker of metastatic gastrointestinal stromal tumors. Oncoimmunology 7(5):e1420450, 2018. e-Pub 2018. PMID: 29721368.
8. Chen J, Zaidi S, Rao S, Chen JS, Phan L, Farci P, Su X, Shetty K, White J, Zamboni F, Wu X, Rashid A, Pattabiraman N, Mazumder R, Horvath A, Wu RC, Li S, Xiao C, Deng CX, Wheeler DA, Mishra B, Akbani R, Mishra L. Analysis of Genomes and Transcriptomes of Hepatocellular Carcinomas Identifies Mutations and Gene Expression Changes in the Transforming Growth Factor-β Pathway. Gastroenterology 154(1):195-210, 2018. e-Pub 2017. PMID: 28918914.
9. Dibra D, Xia X, Gagea M, Lozano G, Li S. A spontaneous model of spondyloarthropathies that develops bone loss and pathological bone formation: A process regulated by IL27RA-/- and mutant-p53. PLoS One 13(3):e0193485, 2018. e-Pub 2018. PMID: 29494633.
10. Gabrusiewicz K, Li X, Wei J, Hashimoto Y, Marisetty AL, Ott M, Wang F, Hawke D, Yu J, Healy LM, Hossain A, Akers JC, Maiti SN, Yamashita S, Shimizu Y, Dunner K, Zal MA, Burks JK, Gumin J, Nwajei F, Rezavanian A, Zhou S, Rao G, Sawaya R, Fuller GN, Huse JT, Antel JP, Li S, Cooper L, Sulman EP, Chen C, Geula C, Kalluri R, Zal T, Heimberger AB. Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes. Oncoimmunology 7(4):e1412909, 2018. e-Pub 2018. PMID: 29632728.
11. Li H, Meng QH, Noh H, Batth IS, Somaiah N, Torres KE, Xia X, Wang R, Li S. Detection of circulating tumor cells from cryopreserved human sarcoma peripheral blood mononuclear cells. Cancer Lett 403:216-223, 2017. e-Pub 2017. PMID: 28652021.
12. Gu S, Nguyen BN, Rao S, Li S, Shetty K, Rashid A, Shukla V, Deng CX, Mishra L, Mishra B. Alcohol, stem cells and cancer. Genes Cancer 8(9-10):695-700, 2017. PMID: 29234487.
13. Hodges TR, Ott M, Xiu J, Gatalica Z, Swensen J, Zhou S, Huse JT, de Groot J, Li S, Overwijk WW, Spetzler D, Heimberger AB. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro Oncol 19(8):1047-1057, 2017. PMID: 28371827.
14. Rao S, Zaidi S, Banerjee J, Jogunoori W, Sebastian R, Mishra B, Nguyen BN, Wu RC, White J, Deng C, Amdur R, Li S, Mishra L. Transforming growth factor-β in liver cancer stem cells and regeneration. Hepatology Communications 1(6):477-493, 2017. PMID: 29404474.
15. Satelli A, Batth I, Brownlee Z, Mitra A, Zhou S, Noh H, Rojas CR, Li H, Meng QH, Li S. EMT circulating tumor cells detected by cell-surface vimentin are associated with prostate cancer progression. Oncotarget 8(30):49329-49337, 2017. PMID: 28521303.
16. Mitra A, Yan J, Xia X, Zhou S, Chen J, Mishra L, Li S. IL6 mediated inflammatory loop reprograms normal to EMT(+) metastatic CSCs in pre-neoplastic liver of TGFβ deficient β2SP(+/-) mice. Hepatology 65(4):1222-1236, 2017. PMID: 27863449.
17. Hu J, Bernatchez C, Zhang L, Xia X, Kleinerman ES, Hung MC, Hwu P, Li S. Induction of NKG2D Ligands on Solid Tumors Requires Tumor-Specific CD8(+) T Cells and Histone Acetyltransferases. Cancer Immunol Res 5(4):300-311, 2017. PMID: 28223282.
18. Batth IS, Mitra A, Manier S, Ghobrial IM, Menter D, Kopetz S, Li S. Circulating Tumor Markers: Harmonizing the yin and yang of CTCs and ctDNA for precision medicine. Ann Oncol 28(3):466-477, 2017. PMID: 27998963.
19. Lu Y, Li S, Zhu S, Gong Y, Shi J, Xu L. Methylated DNA/RNA in Body Fluids as Biomarkers for Lung Cancer. Biol Proced Online 19:2, 2017. e-Pub 2017. PMID: 28331435.
20. Dibra D, Mitra A, Newman M, Xia X, Keenan C, Cutrera JJ, Mathis JM, Wang XJ, Myers J, Li S. IL27 controls skin tumorigenesis via accumulation of ETAR-positive CD11b cells in the pre-malignant skin. Oncotarget 7(47):77138-77151, 2016. PMID: 27738312.
21. Noh H, Yan J, Hong S, Kong LY, Gabrusiewicz K, Xia X, Heimberger AB, Li S. Discovery of cell surface vimentin targeting mAb for direct disruption of GBM tumor initiating cells. Oncotarget. e-Pub 2016. PMID: 27713131.
22. Dibra D, Mitra A, Newman M, Xia X, Cutrera JJ, Gagea M, Kleinerman ES, Lozano G, Li S. Lack of immunomodulatory Interleukin-27 enhances oncogenic properties of mutant p53 in vivo. Clin Cancer Res 22(15):3876-83, 2016. PMID: 26979394.
23. Satelli A, Hu J, Xia X, Li S. Potential Function of Exogenous Vimentin on the Activation of Wnt Signaling Pathway in Cancer Cells. J Cancer 7(13):1824-1832, 2016. e-Pub 2016. PMID: 27698922.
24. Satelli A, Batth IS, Brownlee Z, Rojas C, Meng QH, Kopetz S, Li S. Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients. Sci Rep 6:28910, 2016. e-Pub 2016. PMID: 27363678.
25. Yan J, Mitra A, Hu J, Cutrera JJ, Xia X, Doetschman T, Gagea M, Mishra L, Li S. Corrigendum to "Interleukin-30 (IL27p28) alleviates experimental sepsis by modulating cytokine profile in NKT cells". J Hepatol 64(5):1128-36, 2016. PMID: 26767500.
26. Luk BT, Fang RH, Hu CM, Copp JA, Thamphiwatana S, Dehaini D, Gao W, Zhang K, Li S, Zhang L. Safe and immunocompatible nanocarriers cloaked in RBC membranes for drug delivery to treat solid tumors. Theranostics 6(7):1004-11, 2016. e-Pub 2016. PMID: 27217833.
27. Chen J, Raju GS, Jogunoori W, Menon V, Majumdar A, Chen JS, Gi YJ, Jeong YS, Phan L, Belkin M, Gu S, Kundra S, Mistry NA, Zhang J, Su X, Li S, Lin SH, Javle M, McMurray JS, Rahlfs TF, Mishra B, White J, Rashid A, Beauchemin N, Weston BR, Shafi MA, Stroehlein JR, Davila M, Akbani R, Weinstein JN, Wu X, Mishra L. Mutational Profiles Reveal an Aberrant TGF-β-CEA Regulated Pathway in Colon Adenomas. PLoS One 11(4):e0153933, 2016. PMID: 27100181.
28. Dibra D, Xia X, Mitra A, Cutrera JJ, Lozano G, Li S. Mutant p53 in Concert with an Interleukin-27 receptor alpha deficiency causes spontaneous liver inflammation, fibrosis, and steatosis in mice. Hepatology 63(3):1000-12, 2016. PMID: 26637970.
29. Chen J, Yao ZX, Chen JS, Gi YJ, Muñoz NM, Kundra S, Herlong HF, Jeong YS, Goltsov A, Ohshiro K, Mistry NA, Zhang J, Su X, Choufani S, Mitra A, Li S, Mishra B, White J, Rashid A, Wang AY, Javle M, Davila M, Michaely P, Weksberg R, Hofstetter WL, Finegold MJ, Shay JW, Machida K, Tsukamoto H, Mishra L. TGF-β/β2-spectrin/CTCF-regulated tumor suppression in human stem cell disorder Beckwith-Wiedemann syndrome. J Clin Invest 126(2):527-42, 2016. e-Pub 2016. PMID: 26784546.
30. Yan J, Mitra A, Hu J, Cutrera JJ, Xia X, Doetschman T, Gagea M, Mishra L, Li S. Interleukin-30 (IL27p28) alleviates experimental sepsis by modulating cytokine profile in NKT cells. J Hepatol 64(5):1128-1136. e-Pub 2016. PMID: 26767500.
31. Hu J, Batth IS, Xia X, Li S. Regulation of NKG2D(+)CD8(+) T-cell-mediated antitumor immune surveillance: Identification of a novel CD28 activation-mediated, STAT3 phosphorylation-dependent mechanism. Oncoimmunology 5(12):e1252012, 2016. e-Pub 2016. PMID: 28123894.
32. Mitra A, Satelli A, Xia X, Cutrera J, Mishra L, Li S. Cell-surface Vimentin: A mislocalized protein for isolating csVimentin+CD133(-) novel stem-like hepatocellular carcinoma cells expressing EMT markers. International Journal of Cancer 137(2):491-6, 2015. PMID: 25487874.
33. Yan J, Kong LY, Hu J, Gabrusiewicz K, Dibra D, Xia X, Heimberger AB, Li S. FGL2 as a multimodality regulator of tumor-mediated immune suppression and therapeutic target in gliomas. Journal of the National Cancer Institute 107(8):1-10, 2015. PMID: 25971300.
34. Cutrera J, King G, Jones P, Gumpel E, Kicenuik K, Xia X, Li S. Safe and Effective Treatment of Spontaneous Neoplasms with Interleukin 12 Electro-Chemo-Gene Therapy. Journal of Cellular and Molecular Medicine 19(3):664-675, 2015. PMID: 25628149.
35. Satelli A, Mitra A, Brownlee Z, Xia X, Bellister S, Overman MJ, Kopetz S, Ellis LM, Meng QH, and Li S. Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression. Clinical Cancer Research 21(4):899-906, 2015. PMID: 25516888.
36. Noh H, Hu J, Wang X, Xia X, Satelli A, Li S. Immune checkpoint regulator PD-L1 expression on tumor cells by contacting CK11b positive bone marrow derived stromal cells. Cell Communications and Signaling 13(14), 2015. PMID: 25889536.
37. Satelli A, Brownlee Z, Mitra A, Meng QH, Li S. Circulating Tumor Cell Enumeration with a Combination of Epithelial Cell Adhesion Molecule- and Cell-Surface Vimentin-Based Methods for Monitoring Breast Cancer Therapeutic Response. Clinical Chemistry 61(1):259-266, 2015. PMID: 25336717.
38. Mitra A, Satelli A, Yan J, Xueqing X, Gagea M, Hunter CA, Mishra L, Li S. IL30 attenuates liver fibrosis through inducing NKG2D-Rae1 interaction between NKT and activated hepatic stellate cells in mice. Hepatology 60(6):2027-39, 2014. e-Pub 2014. PMID: 25351459.
39. Lu J, Zhao W, Huang Y, Liu H, Marquez R, Gibbs R, Li J, Venkatarmanan R, Xi L, Li S, Li S. Targeted Delivery of Doxorubicin by Folic Acid-Decorated Dual Functional Nanocarrier. Molecular Pharmaceutics 11(11):4164-78, 2014. PMID: 25265550.
40. Satelli A, Mitra A, Cutrera JJ, Devarie M, Xia X, Ingram DR, Dibra D, Somaiah N, Torres KE, Ravi V, Ludwig JA, Kleinerman ES, Li S. Universal Marker and Detection Tool for Human Sarcoma Circulating Tumor Cells. Cancer Research 74(6):1645-1650, 2014. PMID: 24448245.
41. Hu J, Vien LT, Xia X, Bover L, Li S. Generation of a monoclonal antibody against the glycosylphosphatidylinositol-linked protein Rae-1 using genetically engineered tumor cells. Biological Procedures Online, 2014.
42. Hu J, Zhu S, Xia X, Zhang L, Kleinerman ES, Li S. CD8+T cell-specific induction of NKG2D receptor by doxorubicin plus interleukin-12 and its contribution to CD8+T cell accumulation in tumors. Molecular Cancer, 2014.
43. Cutrera J, King G, Jones P, Kicenuik K, Gumpel E, Xia X, Li S. Safety and Efficacy of Tumor-Targeted Interleukin 12 Gene Therapy in Treated and Non-Treated, Metastatic Lesions. Current Gene Therapy 15(1):44-54, 2014. PMID: 25429465.
44. Denada D, Li S. The cell-to-cell coordination between activated T cells and CpG-stimulated macrophages synergistically induce elevated levels of IL-10 via NF-kappaB1, STAT3, and CD40/CD154. Cell Communication and Signaling 2013, 2013. PMID: 24330710.
45. Fang RH, Hu CM, Chen KN, Luk BT, Carpenter CW, Gao W, Li S, Zhang DE, Lu W, Zhang L. Lipid-insertion enables targeting functionalization of erythrocyte membrane-cloaked nanoparticles. Nanoscale 5(19):8884-8, 2013. e-Pub 2013. PMID: 23907698.
46. Irwin ME, Nelson LD, Santigiao O'Farrill JM, Knouse PD, Miller CP, Palla SL, Siwak DR, Mills GB, Estrov Z, Li S, Sornblau SM, Hughes DP, Chandra J. Small Molecule ErbB Inhibitors Decrease Proliferative Signaling and Promote Apoptosis in Phildelphia Chromosome-Positive Acute Lymphoblastic Leukemia. PLoSOne 8(8):e70608, 2013. PMID: 23936456.
47. Shiomitsu K, Xia X, Waite K, Sehgal I, Li S. Evaluation of the Aurora Kinase Inhibitor, ZM447439, in Canine Malignant Lymphoid Cells in Vitro. Open Journal of Veterinary Medicine 3:29-38. e-Pub 2013.
48. Cutrera J, Johnson B, Ellis L, Li S. Intraosseous Inoculation of Tumor Cells into Bone Marrow Promotes Distant Metastatic Tumor Development: a Novel Tool for Mechanistic and Therapeutic Studies. Cancer Letters 329(1):68-73, 2013. e-Pub 2012. PMID: 23111105.
49. Liu Z, Liu JQ, Talebian F, Wu LC, Li S, Bai XF. IL-27 enhances the survival of tumor antigen-specific CD8(+) T cells and programs them into IL-10-producing, memory precursor-like effector cells. Eur J Immunol 43(2):468-79, 2013. e-Pub 2013. PMID: 23225163.
50. Cutrera J, Dibra D, Xia X, Li S. Intricacies for Post-translational tumor-targeted cytokine gene therapy. Mediators of Inflammation 2013(Article ID 378971):9 pages, 2013. PMID: 24369443.
51. Dibra D, Cutrera J, Xia X, Kallakury B, Mishra L, Li S. Interleukin-30: A novel antiinflammatory cytokine candidate for prevention and treatment of inflammatory cytokine-induced liver injury. Hepatology 55(4):1204-14, 2012. e-Pub 2012. PMID: 22105582.
52. Dibra D, Cutrera JJ, Li S. Coordination between TLR9 Signaling in Macrophages and CD3 Signaling in T Cells Induces Robust Expression of IL-30. J Immunol 188(8):3709-15, 2012. e-Pub 2012. PMID: 22407920.
53. Flanagan M, Gimble JM, Yu G, Xia X, Bunnell BA, Li S. Competitive DNA transfection formulation via electroporation for human adipose stem cells and mesenchymal stem cells. Biol Proced Online 14(1):7, 2012. e-Pub 2012. PMID: 22512891.
54. Zolochevska O, Xia X, Williams BJ, Ramsay A,Li S, Figueiredo ML.. Sonoporation Delivery of Interleukin-27 Gene Therapy Efficiently Reduces Prostate Tumor Cell Growth In Vivo. Human Gene Therapy 22(12):1537-50, 2011. PMID: 21801027.
55. Cutrera J, Dibra D, Xia X, Hasan A, Reed S, Li S. Discovery of a Linear Peptide for Improving Tumor Targeting of Gene Products and Treatment of Distal Tumors by IL12 Gene Therapy. Mol Ther 19(8):1468-77, 2011. e-Pub 2011. PMID: 21386825.
56. Hu J, Liu X, Hughes D, Esteva FJ, Liu B, Chandra J,Li S. Herceptin conjugates linked by EDC boost direct tumor cell death via programmed tumor cell necrosis. PLoS ONE 6(8):e23270.doi:10.1371/journal.pone.0023270, 2011. PMID: 21853100.
57. Flanagan M, Gimble JM, Yu G, Wu X, Xia X, Hu J, Yao S, Li S. Competitive electroporation formulation for cell therapy. Cancer Gene Ther 18(8):579-86, 2011. e-Pub 2011. PMID: 21660061.
58. Reed SD, Li S. Pre-clinical toxicity assessment of tumor-targeted interleukin-12 low-intensity electrogenetherapy. Cancer Gene Ther 18(4):265-74, 2011. e-Pub 2011. PMID: 21233859.
59. Dibra D, Cutrera J, Xia X, Li S. WSX1 Expression in Tumors Induces Immune Tolerance via Suppression of Effector Immune Cells. PLoS One 6(4):e19072.doi:10.1371/journal.pone.0019072, 2011. e-Pub 2011. PMID: 21559505.
60. Reed SD, Fulmer A, Buckholz J, Zhang B, Cutrera J, Shiomitsu K, Li S. Bleomycin/interleukin-12 electrochemogenetherapy for treating naturally occurring spontaneous neoplasms in dogs. Cancer Gene Ther 17(7):457-64, 2010. e-Pub 2010. PMID: 20150931.
61. Zhu S, Lee DA, Li S. IL-12 and IL-27 sequential gene therapy via intramuscular electroporation delivery for eliminating distal aggressive tumors. J Immunol 184(5):2348-54, 2010. PMID: 20139275.
62. Cutrera J, Dibra D, Xia X, Li S. Enhancement of reporter gene detection sensitivity by insertion of specific mini-peptide-coding sequences. Cancer Gene Ther 17(2):131-140, 2010. e-Pub 2009. PMID: 19713998.
63. Dibra D, Cutrera JJ, Xia X, Birkenbach MP, Li S. Expression of WSX1 in tumors sensitizes IL-27 signaling-independent natural killer cell surveillance. Cancer Res 69(13):5505-13, 2009. e-Pub 2009. PMID: 19549909.
64. Shiomitsu K, Sajo E, Xia X, Hunley DW, Mauldin GE,Li S, Mauldin GN. Radiosensitivity of canine osteosarcoma cells transfected with wild-type p53 in vitro. Vet Comp Oncol 6(3):193-200, 2008. PMID: 19178679.
65. Craig R, Cutrera J, Zhu S, Xia X, Lee YH,Li S. Administering plasmid DNA encoding tumor vessel-anchored IFN-alpha for localizing gene product within or into tumors. Mol Ther 16(5):901-6, 2008. e-Pub 2008. PMID: 18388923.
66. Zhu S, Waguespack M, Barker SA, Li S. Doxorubicin directs the accumulation of interleukin-12 induced IFN gamma into tumors for enhancing STAT1 dependent antitumor effect. Clin Cancer Res 15:13(14):4252-60, 2007. PMID: 17634555.
67. Liu J, Xia X, Torrero M, Barrett R, Shillitoe EJ, Li S,. The mechanism of exogenous B7.1-enhanced IL-12-mediated complete regression of tumors by a single electroporation delivery. Int J Cancer 119(9):2113-8, 2006. PMID: 16823840.
68. Torrero MN, Xia X, Henk W, Yu S, Li S,. Stat1 deficiency in the host enhances interleukin-12-mediated tumor regression. Cancer Res 66(8):4461-7, 2006. PMID: 16618773.
69. Torrero MN, Henk WG,Li S,. Regression of high-grade malignancy in mice by bleomycin and interleukin-12 electrochemogenetherapy. Clin Cancer Res 1(12):257-63, 2006. PMID: 16397050.
70. Li S, Zhang L, Torrero M, Cannon M, Barret R. Administration route- and immune cell activation-dependent tumor eradication by IL12 electrotransfer. Mol Ther 12(5):942-9, 2005. e-Pub 2005. PMID: 15953768.
71. Li S, Wilkinson M, Xia X, David M, Xu L, Purkel-Sutton A, Bhardwaj A.. Induction of IFN-regulated factors and antitumoral surveillance by transfected placebo plasmid DNA. Mol Ther 11(1):112-9, 2005. PMID: 15585412.
72. Li S, Hanna E, Breau R, Ratanatharathorn V, Xia X, Suen J. Preferential expression of hPGFS in primary SCCHN and tumour cell lines derived from respiratory and digestive organs. Br J Cancer 8:90(5):1093-9, 2004. PMID: 14997212.
73. Li S, Xia X, Mellieon FM, Liu J, Steele S. Candidate genes associated with tumor regression mediated by intratumoral IL-12 electroporation gene therapy. Mol Ther 9(3):347-54, 2004. PMID: 15006601.
74. Wang J, Hamilton JI, Carter MS,Li S, Wilkinson MF. Alternatively spliced TCR mRNA induced by disruption of reading frame. Science 297(5578):108-110, 2002. PMID: 12098701.
75. Pumphrey CY, Theus AM,Li S, Parrish RS, Sanderson RD. Neoglycans, carbodiimide-modified glycosaminoglycans: a new class of anticancer agents that inhibit cancer cell proliferation and induce apoptosis. Cancer Res 62(13):3722-3728, 2002. PMID: 12097281.
76. Li S, Zhang X, Xia X. Regression of tumor growth and induction of long-term antitumor memory by interleukin 12 electro-gene therapy. J Natl Cancer Inst 15(94):762-8, 2002. PMID: 12011227.
77. Wang J, Vock VM, Li S, Olivas OR, Wilkinson MF. A quality control pathway that down-regulates aberrant T-cell receptor (TCR) transcripts by a mechanism requiring UPF2 and translation. J Biol Chem 24(277):18489-93, 2002. e-Pub 2002. PMID: 11889124.
78. Dornhoffer JL, Danner C, Li S. Natriuretic peptide receptors in the human endolymphatic sac. Arch Otolaryngol Head Neck Surg 128(4):379-83, 2002. PMID: 11926910.
79. Li S, Xia X, Zhang X, Suen J. Regression of tumors by IFN-alpha electroporation gene therapy and analysis of the responsible genes by cDNA array. Gene Ther 9(6):390-7, 2002. PMID: 11960315.
80. Mühlemann O, Mock-Casagrande CS, Wang J, Li S, Custódio N, Carmo-Fonseca M, Wilkinson MF, Moore MJ. Precursor RNAs harboring nonsense codons accumulate near the site of transcription. Mol Cell 8(1):33-43, 2001. PMID: 11511358.
81. Hanna E, Zhang X, Woodlis J, Breau R, Suen J, Li S. Intramuscular electroporation delivery of IL-12 gene for treatment of squamous cell carcinoma located at distant site. Cancer Gene Ther 8(3):151-7, 2001. PMID: 11332985.
82. Li S, MacLaughlin FC, Fewell JG, Gondo M, Wang J, Nicol F, Dean DA, Smith LC. Muscle-specific enhancement of gene expression by incorporation of SV40 enhancer in the expression plasmid. Gene Ther 8(6):494-7, 2001. PMID: 11313829.
83. Hanna E, Shrieve DC, Ratanatharathorn V, Xia X, Breau R, Suen J, Li S. A novel alternative approach for prediction of radiation response of squamous cell carcinoma of head and neck. Cancer Res 15(61):2376-80, 2001. PMID: 11289099.
84. Li S, MacLaughlin FC, Fewell JG, Li Y, Mehta V, French MF, Nordstrom JL, Coleman M, Belagali NS, Schwartz RJ, Smith LC. Increased level and duration of expression in muscle by co-expression of a transactivator using plasmid systems. Gene Ther 6(12):2005-11, 1999. PMID: 10637452.
85. Li S, Wilkinson MF. Site-directed mutagenesis: a two-step method using PCR and DpnI. Biotechniques 23(4):588-90, 1997. PMID: 9343667.
86. Li S, Leonard D, Wilkinson MF. T cell receptor (TCR) mini-gene mRNA expression regulated by nonsense codons: a nuclear-associated translation-like mechanism. Journal of Experimental Medicine 185(6):985-992, 1997. PMID: 9091590.
87. Li S, Ke S, Budde RJ. The C-terminal Src kinase (Csk) is widely expressed, active in HT-29 cells that contain activated Src, and its expression is downregulated in butyrate-treated SW620 cells. Cell Biol Int 20(11):723-9, 1996. PMID: 8979366.
88. Carter MS, Li S, Wilkinson MF. A splicing-dependent regulatory mechanism that detects translation signals. EMBO Journal 15(21):5965-5975, 1996. PMID: 8918474.
89. Maiti S, Doskow J,Li S, Nhim RP, Lindsey JS, Wilkinson MF. The Pem homeobox gene. Androgen-dependent and -independent promoters and tissue-specific alternative RNA splicing. J Biol Chem 271(29):17536-46, 1996. PMID: 8663309.
90. Carter MS, Li S, Wilkinson MF. T cell receptor mRNA regulation: A proofreading mechanism. FASEB Journal 10(6):A-1042, 1996.
91. Carter MS, Doskow J, Morris P, Li S, Nhim RP, Sandstedt S, Wilkinson MF. A regulatory mechanism that detects premature nonsense codons in T-cell receptor transcripts in vivo is reversed by protein synthesis inhibitors in vitro. J Biol Chem 48(270):28995-9003, 1995. PMID: 7499432.
92. Li S, Sun G, Budde RJ. Production and characterization of monoclonal antibodies against the recombinant p50csk protein tyrosine kinase: a tool for signal transduction research. Hybridoma 14(4):341-6, 1995. PMID: 8522345.
93. Andrews P, Li S. Partial purification and characterization of galactosidase from cell walls of a nonclimacteris fruit. J Agric. and Food Chemistry(42):2177-2182, 1994.

Invited Articles

1. Hu J, Yan J, Rao G, Latha K, Overwijk WW, Heimberger AB, Li S. The Duality of Fgl2 - Secreted Immune Checkpoint Regulator Versus Membrane-Associated Procoagulant: Therapeutic Potential and Implications. Int Rev Immunol 35(4):325-339, 2016. e-Pub 2014. PMID: 25259408.
2. Dibra D, Mishra L, Li S. Molecular Mechanisms of Oncogene-Induced Inflammation and Inflammation-Sustained Oncogene Activation in Gastrointestinal Tumors: an Underappreciated Symbiotic Relationship. Biochimica et Biophysica Acta - Reviews on Cancer 1846(1):152-160, 2014. PMID: 24821201.
3. Wang X, Li S. Protein mislocalization: Mechanisms, functions and clinical applications in cancer. Biochimica et Biophysica Acta - Reviews on Cancer 1846(1):13-25, 2014. PMID: 24709009.
4. Yan J, Li S. The Role of the Liver in Sepsis. Informa Healthcare, 2014. PMID: 24611785.
5. Mitra A, Mishra L, Li S. Technologies for deriving primary tumor cells for use in personalized cancer therapy. Trends Biotechnol 31(6). e-Pub 2013. PMID: 23597659.
6. Majumdar A, Curley SA, Wu X, Brown P, Hwang JP, Shetty K, Yao ZX, He AR, Li S, Katz L, Farci P, Mishra L. Hepatic stem cells and transforming growth factor β in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 9(9):530-8, 2012. e-Pub 2012. PMID: 22710573.
7. Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci 68(18):3033-46, 2011. e-Pub 2011. PMID: 21637948.
8. Reed SD,Li S. Electroporation Advances in Large Animals. Curr Gene Ther. e-Pub 2009. PMID: 19545229.
9. Craig R, Li S. Function and molecular mechanism of tumor-targeted peptides for delivering therapeutic genes and chemical drugs. Mini Rev Med Chem 6(7):757-64, 2006. PMID: 16842125.
10. Li S. Electroporation gene therapy: new developments in vivo and in vitro. Curr Gene Ther 4(3):309-316, 2004. PMID: 15384944.
11. Torrero MN,Li S. Growth factor receptors: targets for gene therapy and immunotherapy for cancer treatment. Gene Therapy and Molecular Biology(8):175-180, 2004.
12. Li S, Benninger M. Applications of muscle electroporation gene therapy. Curr Gene Ther 2(1):101-5, 2002. PMID: 12108971.
13. Li S. IL-12-Based therapy of malignancies. Drugs of Today 37(9):629-637, 2001. PMID: 12743634.
14. Li S, Wilkinson MF. Nonsense surveillance in lymphocytes?. Immunity 8(2):135-41, 1998. PMID: 9491995.

Book Chapters

1. Hu J, Cutrera J, Li S. The Impact of Non-electrical Factors on Electrical Gene Transfer. In: Electroporation Protocols Preclinical and Clinical Gene Medicine. 2nd. Humana Press, 47-54, 2014.
2. Hu J, Li S. Electroporation Formulation for Cell Therapy. In: Electroporation Protocols Preclinical and Clinical Gene Medicine. 2nd. Humana Press, 55-60, 2014.
3. Cutrera J, King G, Jones P, Gumpel E, Xia X, Li S. Managing Local Swelling Following Intratumoral Electro-Chemo-Gene Therapy. In: Electroporation Protocols Preclinical and Clinical Gene Medicine. 2nd. Humana Press, 233-239, 2014.

Books (edited and written)

1. Li S, Cutrera J, Heller R, Teissie J. Electroporation protocols: Experimental and Clinical Gene Medicine. 2nd. Humana Press, 2014.